2cureX was founded in 2006 as a spin-out from the Carlsberg Research center in Copenhagen, with the vision of improving treatment efficiency for cancer patients. From its inception, 2cureX has been closely related to the major Cancer hospitals in the Nordics, Germany and The UK.
2cureX developed the IndiTreat® test; IndiTreat® matches the individual cancer patient with the most effective cancer treatment.
The IndiTreat® test for colorectal cancer has a European CE-IVD approval and the company is conducting ongoing multi-center clinical validation trials with leading Cancer hospitals within Ovarian Cancer and Pancreatic Cancer.
2cureX Headquarters is based in Copenhagen, Denmark, and the company’s shares are listed at Nasdaq First North in Stockholm (2CUREX.ST).